
This study revealed promising results in the fight against multiple myeloma (MM), an incurable blood cancer. Dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, has displayed significant anti-MM activity in Phase II clinical trials. The study also found that combining dinaciclib with BH3 mimetics like ABT-199 or A-1155463 shows a synergistic effect, especially in MM patients with high dependence on MCL-1. This breakthrough offers hope for MM patients, including those with cytogenetic alterations and poor prognosis. Researchers are now exploring CDK9 inhibition as a targeted therapy for MM patients.
Like
Save
Share